ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2015

Dec. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Account Receivable risk

The following table identifies customers with accounts receivable that individually exceed 10% of the Company’s total accounts receivable for December 31, 2014 and 2013:

	2014			2013
Ovation Pharma	85,000	44	%	135,035	52	%
Sothema Laboratories	52,187	27	%	-	-
Wal-Mart	20,580	11	%	37,963	15	%

Revenues consist primarily of product sales and licensing rights to market and commercialize our products.  The following table identifies customers with revenues that individually exceed 10% of the Company’s total revenues for the year ended December 31, 2014:

Sothema Laboratories	245,380	23	%
Ovation Pharma	175,000	17	%
Wal-Mart	171,600	16	%

Schedule of Inventory

Raw materials	$	94,566
Work in process		24,122
Finished goods		172,401
Total	$	291,089

		Amount
		2014		2013
Raw materials	$	90,934		$	123,379
Finished goods		84,249			63,948
Packaging supplies		100,251			-
Inventory reserve		(9,476	)		(9,476	)
Total at December 31, 2014		265,959			177,851

Schedule of Intangible Assets and Goodwill

 Amortizable intangible assets consist of the following:

June 30, 2015
	Amount		Accumulated Amortization		Net Amount		Useful Lives (years)
Patent & Trademarks	$	417,598	$	39,158	$	378,439		7 - 15
Customer Contracts		611,119		92,818		518,301		10
Sensum+® License		234,545		38,227		196,318		10
Vesele® trademark		25,287		2,304		22,983		10
Novalere Mfg Contract		4,681,000		184,975		4,496,026		10
Total	$	5,969,549	$	357,482	$	5,612,067
December 31, 2014
	Amount		Accumulated Amortization		Net Amount		Useful Lives (years)
Patent & Trademarks	$	264,321	$	23,671	$	240,650		7 - 15
Customer Contracts		611,119		62,262		548,857		10
Sensum+® license		272,545		31,250		241,295		10
Vesele® trademark		25,287		717		24,570		10
Total	$	1,173,272	$	117,900	$	1,055,372

			Accumulated					Useful Lives
	Amount		Amortization			Net Amount		(years)
Patents and trademarks	$	264,321	$	(23,671	)	$	240,650	7 - 14
Customer contracts		611,119		(62,262	)		548,857	10
Sensum+™ (formally called CIRCUMserum™) license		272,545		(31,250	)		241,295	10
Vesele trademark		25,287		(717	)		24,570	8
Outstanding at December 31, 2014		1,173,272		(117,900	)		1,055,372

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

	As of June 30,
	2015		2014
Gross number of shares excluded:
Restricted Stock units		19,033,482		7,937,791
Stock options		134,000		62,000
Convertible Notes		2,281,128		825,000
Warrants		1,630,973		630,973
Total		23,079,583		9,455,764

	As of December 31
	2014		2013
Gross number of shares excluded:
Restricted stock units		8,270,239		6,300,000
Stock options		113,000		21,000
Convertible notes payable		2,115,195		2,378,287
Warrants		630,973		380,973
Total		11,129,407		9,080,260